indicated in table ii table iii and fig1 the preferred compounds for use in the methodology of this invention are 1 substituted imidazoles of formula i wherein r is h r 1 is c 1 c 9 alkyl 3 methamindole or para substituted aryl hydroxy 3 substituted pyridines of formula ii wherein r 2 is 3 indolo the thromboxane synthase inhibitors of the present invention may be administered in the form of pharmaceutically acceptable nontoxic anionic salts preferred salts for this purpose include hydrochloride nitrate sulfate and tartrate salts the thromboxane synthase inhibitors of the present invention can be administered in dosages of 0 1 to 200 mg per kg per day preferably 0 1 to 50 mg per kg per day most preferably 0 1 to 10 mg per kg per day for purposes of administration the thromboxane synthase inhibitors of the present invention can be combined with conventional compatible organic or inorganic pharmaceutical carrier materials known in the art such materials include for example water gelatin gums lactose starches magnesium stearate talc vegetable oils polyalkylene glycols petroleum jelly and the like such pharmaceutical preparations may be in unit dosage form and may additionally contain other therapeutically valuable substances or conventional pharmaceutical adjuvants such as preservatives stabilizing agents wetting agents emulsifying agents buffers and the like the pharmaceutical preparations can be in conventional solid dosage forms such as tablets capsules dragees and the like conventional semi solid forms such as ointments and creams conventional liquid forms such as solutions suspension emulsions and the like and other conventional dosage forms such as dry ampules suppositories and the like such preparations may be submitted to conventional pharmaceutical expedients such.